Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20240] to ICOS Ligand/ICOSL
- Suitable for: WB, IP
- Reacts with: Human
Overview
-
Product name
Anti-ICOS Ligand/ICOSL antibody [EPR20240]
See all ICOS Ligand/ICOSL primary antibodies -
Description
Rabbit monoclonal [EPR20240] to ICOS Ligand/ICOSL -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species IP HumanWB Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: His-tagged recombinant human ICOS ligand/ICOSL protein; Untreated and PNGase F treated JAR whole cell lysates; Untreated and tumor necrosis factor-alpha (TNF-alpha, ab9642) 200 unit/ml for 24 hours treated HUVEC whole cell lysates. IP: JAR whole cell lysate.
-
General notes
This product was previously labelled as ICOS Ligand
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20240 -
Isotype
IgG -
Research areas
Images
-
Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262) at 1/20000 dilution + His-tagged recombinant human ICOS ligand/ICOSL protein at 0.01 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 33 kDa
Observed band size: 50 kDa why is the actual band size different from the predicted?
Exposure time: 10 secondsBlocking/Dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262) at 1/1000 dilution
Lane 1 : Untreated JAR (Human placenta choriocarcinoma cell line) whole cell lysate
Lane 2 : JAR whole cell lysate treated with PNGase F
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 33 kDa
Exposure time: 30 secondsBlocking/Dilution buffer: 5% NFDM/TBST.
ICOS ligand/ICOSL is highly glycosylated (PMID 11983910).
Observed band sizes: 60 kDa (glycosylated form); 35 kDa (non-glycosylated form).
-
All lanes : Anti-ICOS Ligand/ICOSL antibody [EPR20240] (ab209262) at 1/1000 dilution
Lane 1 : Untreated HUVEC (Human umbilical vein endothelial cell line) whole cell lysate
Lane 2 : HUVEC whole cell lysate treated with tumor necrosis factor-a (TNF-alpha, ab9642) 200 unit/ml for 24 hours
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 33 kDa
Observed band size: 60 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsBlocking/Dilution buffer: 5% NFDM/TBST.
The level of ICOS Ligand/ICOSL expression can be elevated by TNF-alpha treatment (PMID 11983910).
-
ICOS Ligand/ICOSL was immunoprecipitated from 0.35 mg of JAR (Human placenta choriocarcinoma cell line) whole cell lysate with ab209262 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab209262 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1: JAR whole cell lysate, 10 μg (Input).
Lane 2: ab209262 IP in JAR whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab209262 in JAR whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
-